Eli Lilly and Co (LLY) : Swiss National Bank scooped up 196,000 additional shares in Eli Lilly and Co during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 3, 2016. The investment management firm now holds a total of 3,249,843 shares of Eli Lilly and Co which is valued at $268,827,013.Eli Lilly and Co makes up approximately 0.42% of Swiss National Bank’s portfolio.
Other Hedge Funds, Including , Rathbone Brothers Plc boosted its stake in LLY in the latest quarter, The investment management firm added 5,900 additional shares and now holds a total of 95,535 shares of Eli Lilly and Co which is valued at $7,902,655. Eli Lilly and Co makes up approx 0.43% of Rathbone Brothers Plc’s portfolio. Spinnaker Trust added LLY to its portfolio by purchasing 2,690 company shares during the most recent quarter which is valued at $222,517. Eli Lilly and Co makes up approx 0.03% of Spinnaker Trust’s portfolio.Daiwa Securities Group reduced its stake in LLY by selling 72,300 shares or 64.7% in the most recent quarter. The Hedge Fund company now holds 39,450 shares of LLY which is valued at $3,290,130. Eli Lilly and Co makes up approx 0.02% of Daiwa Securities Group’s portfolio.Newsquare Capital boosted its stake in LLY in the latest quarter, The investment management firm added 1,419 additional shares and now holds a total of 9,528 shares of Eli Lilly and Co which is valued at $794,635. Eli Lilly and Co makes up approx 0.19% of Newsquare Capital’s portfolio.
Eli Lilly and Co opened for trading at $81.44 and hit $81.85 on the upside on Monday, eventually ending the session at $81.6, with a gain of 0.05% or 0.04 points. The heightened volatility saw the trading volume jump to 42,27,300 shares. Company has a market cap of $90,074 M.
On the company’s financial health, Eli Lilly and Co reported $0.86 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.85. The company had revenue of $5404.80 million for the quarter, compared to analysts expectations of $5157.09 million. The company’s revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.90 EPS.
Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers develops manufactures and market products in two segments: human pharmaceutical products and animal health products. The Company’s products are sold in approximately 120 countries. The Company’s human pharmaceutical business segment sells medicines which are discovered or developed by its scientists. Its animal health business segment operates through the Company’s Elanco division which develops manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States Puerto Rico and 11 other countries. Its products include endocrinology products neuroscience products oncology products cardiovascular products products for food animals products for companion animals and Novartis AH products.